Table 1 Baseline biochemical and physical characteristics of the study populations.
HCV genotype 1 (n = 15) | Control genotype 1 (n = 5) | HCV genotype 3 (n = 22) | Control genotype 3 (n = 5) | |
|---|---|---|---|---|
Gender (male/female) | 8/7 | 2/3 | 10/12 | 2/3 |
Age (years) | 48.1 ± 12.6 | 49.3 ± 10.3 | 37.5 ± 9.5 | 49.3 ± 10.3 |
ALT U/l) | 80.2 ± 69.3 | 61.4 ± 40.9 | 40.5 ± 34.2 | 61.4 ± 40.9 |
AST (U/l) | 76.7 ± 67.6 | 37.4 ± 17.6 | 58.4 ± 32.1 | 37.4 ± 17.6 |
γ-GT (U/l) | 133.7 ± 23.3 | 60 ± 29.8 | 97.8 ± 10.6 | 60 ± 29.8 |
Total bilirubin (mg/dl) | 1.4 ± 0.2 | 0.7 ± 0.2 | 0.9 ± 0.5 | 0.7 ± 0.2 |
Prothrombin time (%) | 103 ± 11.2 | 108.6 ± 12.1 | 114 ± 9 | 108.6 ± 12.1 |
Triglycerides (mg/dl) | 153.2 ± 94.3 | 137.6 ± 62.9 | 194.5 ± 86.2 | 137.6 ± 62.9 |
Cholesterol (mg/dl) | 201.8 ± 52.5 | 201 ± 43.6 | 208.6 ± 37.2 | 201 ± 43.6 |
Virological response | 11/4 (73.3%) | / | 19/3 (86.3%) | / |
Ascites | None | none | none | none |
FibroScan (kPa) Pre-therapy | 8.8 ± 5.4 | 9.8 ± 3.9 | 7.5 ± 1.9 | 8.2 ± 2.4 |
FibroScan (kPa) Post-therapy | 7.4 ± 1.8 | 9.5 ± 3.3 | 6.2 ± 1.2 | 8.7 ± 2.9 |